Abiopharma

🔍 GENDELL JEFFREY L ET AL (Director)

Company: IES Holdings, Inc. (IESC)

Report Date: 2026-06-12

Detailed Transactions and Holdings:

• Sold 19,996 shares of Common Stock, par value $0.01 per share at $750.24 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,433,283.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4 shares of Common Stock, par value $0.01 per share at $752.18 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,433,279.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,491 shares of Common Stock, par value $0.01 per share at $758.74 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,425,788.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Sold 10,000 shares of Common Stock, par value $0.01 per share at $760.47 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,415,788.00 | transaction_form_type: 4 | Footnotes: F8, F2
• Sold 2,509 shares of Common Stock, par value $0.01 per share at $761.73 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,413,279.00 | transaction_form_type: 4 | Footnotes: F9, F2
• Sold 6,720 shares of Common Stock, par value $0.01 per share at $764.54 per share (Direct)
  Date: 2026-06-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,406,559.00 | transaction_form_type: 4 | Footnotes: F10, F2

Footnotes:

• F1: All shares of Common Stock reported as sold in this Form 4 were sold by Tontine Capital Partners, L.P., a Delaware limited partnership ("TCP"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.24 to $750.43, inclusive. The reporting person undertakes to provide IES Holdings, Inc. (the "Issuer"), any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: This report is filed jointly by TCP, Tontine Capital Management, L.L.C., a Delaware limited liability company ("TCM"), Tontine Management, L.L.C., a Delaware limited liability company ("TM"), Tontine Capital Overseas Master Fund II, L.P., a Delaware limited partnership ("TCP 2"), Tontine Asset Associates, L.L.C., a Delaware limited liability company ("TAA"), Tontine Associates, L.L.C., a Delaware limited liability company ("TA"), Tontine Capital Overseas GP, L.L.C., a Delaware limited liability company ("TCO"), and Jeffrey L. Gendell ("Mr. Gendell"). Mr. Gendell is the managing member of: (a) TCM, the general partner of TCP; (b) TM; (c) TAA, the general partner of TCP 2; (d) TA; and (e) TCO.
• F3: TCP directly owns 5,477,671 shares of Common Stock, TCM directly owns 1,910,529 shares of Common Stock, TM directly owns 1,410,162 shares of Common Stock, TCP 2 directly owns 710,934 shares of Common Stock, TAA directly owns 96,891 shares of Common Stock, TA directly owns 640,057 shares of Common Stock, TCO directly owns 47,284 shares of Common Stock, Mr. Gendell directly owns 44,599 shares of Common Stock and 65,069 phantom stock units granted to him pursuant to the IES Holdings, Inc. 2006 Equity Incentive Plan, as amended and restated, and Mr. Gendell's adult children own 3,363 shares of Common Stock through trusts for which Mr. Gendell acts as trustee.
• F4: All of the foregoing securities may be deemed to be beneficially owned by Mr. Gendell. The foregoing securities held by TCP may be deemed to be beneficially owned by TCM. The foregoing securities held by TCP 2 may be deemed to be beneficially owned by TAA.
• F5: Mr. Gendell disclaims beneficial ownership of the Issuer's securities reported herein for purposes of Section 16(a) under the Securities Exchange Act of 1934, as amended, or otherwise, except as to securities directly owned by Mr. Gendell or representing Mr. Gendell's pro rata interest in, and interest in the profits of, TCM, TCP, TM, TCP 2, TAA, TA and TCO. TCM disclaims beneficial ownership of the Issuer's securities reported herein for purposes of Section 16(a) under the Securities Exchange Act of 1934, as amended, or otherwise, except as to securities directly owned by TCM or representing TCM's pro rata interest in, and interest in the profits of, TCP.
• F6: TAA disclaims beneficial ownership of the Issuer's securities reported herein for purposes of Section 16(a) under the Securities Exchange Act of 1934, as amended, or otherwise, except as to securities directly owned by TAA or representing TAA's pro rata interest in, and interest in the profits of, TCP 2. TA disclaims beneficial ownership of the Issuer's securities reported herein for purposes of Section 16(a) under the Securities Exchange Act of 1934, as amended, or otherwise, except as to securities directly owned by TA. TM disclaims beneficial ownership of the Issuer's securities reported herein for purposes of Section 16(a) under the Securities Exchange Act of 1934, as amended, or otherwise, except as to securities directly owned by TM. TCO disclaims beneficial ownership of the Issuer's securities reported herein for purposes of Section 16(a) under the Securities Exchange Act of 1934, as amended, or otherwise, except as to securities directly owned by TCO.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $758.74 to $759.31, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: These shares were sold in multiple transactions each at a price of $760.47. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold in each separate transaction described in this footnote.
• F9: These shares were sold in multiple transactions each at a price of $761.73. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold in each separate transaction described in this footnote.
• F10: These shares were sold in multiple transactions each at a price of $764.54. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold in each separate transaction described in this footnote.